このエントリーをはてなブックマークに追加
ID 52840
フルテキストURL
著者
Itoh, Mitsuya Okayama Univ
Iwamoto, Takayuki Okayama Univ
Matsuoka, Junji Okayama Univ
Nogami, Tomohiro Okayama Univ
Motoki, Takayuki Okayama Univ
Shien, Tadahiko Okayama Univ
Taira, Naruto Okayama Univ
Niikura, Naoki Tokai Univ
Hayashi, Naoki St Lukes Int Hosp
Ohtani, Shoichiro Hiroshima City Hosp
Higaki, Kenji Hiroshima City Hosp
Fujiwara, Toshiyoshi Okayama Univ
Doihara, Hiroyoshi Okayama Univ
Symmans, W. Fraser Univ Texas MD Anderson Canc Ctr
Pusztai, Lajos Yale Univ
抄録
We examined estrogen receptor (ER) mRNA expression and molecular subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization. The ER, PR, and HER2 status was determined by IHC as part of routine clinical assessment (N = 501). Gene expression profiling was done with the Affymetrix U133A gene chip. We compared expressions of ESR1 and MKI67 mRNA, distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine therapy index, and the DLDA30 chemotherapy response predictor signature among ER/PR-positive (n = 223), ER-positive/PR-negative (n = 73), ER-negative/PR-positive (n = 20), and triple-negative (n = 185) cancers. All patients received neoadjuvant chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy only if ER or PR > 10 % positive. ESR1 expression was high in 25 % of ER-negative/PR-positive, in 79 % of ER-positive/PR-negative, in 96 % of ER/PR-positive, and in 12 % of triple-negative cancers by IHC. The average MKI67 expression was significantly higher in the ER-negative/PR-positive and triple-negative cohorts. Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like. The relapse-free survival rate of ER-negative/PR-positive patients was equivalent to ER-positive cancers and better than the triple-negative cohort. Only 20-25 % of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers. In this rare subset of patients (i) a second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.
キーワード
Estrogen receptor
Progesteron receptor
cDNA microarray
Breast cancer
Hormone therapy
備考
The final publication is available at www.springerlink.com
発行日
2014-01
出版物タイトル
Breast Cancer Research and Treatment
143巻
2号
出版者
Springer
開始ページ
403
終了ページ
409
ISSN
0167-6806
NCID
AA10623184
資料タイプ
学術雑誌論文
関連URL
http://ousar.lib.okayama-u.ac.jp/metadata/52821
言語
English
著作権者
© Springer Science+Business Media New York 2013
論文のバージョン
author
査読
有り
DOI
Web of Sience KeyUT